Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 Global Opioid Use Disorder (OUD) Market, by Drug Class
1.4.2 Global Opioid Use Disorder (OUD) Market, by Route of Administration
1.4.3 Global Opioid Use Disorder (OUD) Market, by Distribution Channel
1.4.4 Global Opioid Use Disorder (OUD) Market, by Geography
1.5 Methodology for the research
Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.1.1 Market Composition and Scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints
Chapter 3. Strategies Deployed in Opioid Use Disorder (OUD) Market
Chapter 4. Global Opioid Use Disorder (OUD) Market by Drug Class
4.1 Global Buprenorphine Market by Region
4.2 Global Methadone Market by Region
4.3 Global Naltrexone Market by Region
Chapter 5. Global Opioid Use Disorder (OUD) Market by Route of Administration
5.1 Global Parenteral Market by Region
5.2 Global Oral Market by Region
Chapter 6. Global Opioid Use Disorder (OUD) Market by Distribution Channel
6.1 Global Hospital Pharmacies Market by Region
6.2 Global Retail Pharmacies & Stores Market by Region
6.3 Global Online Pharmacies Market by Region
Chapter 7. Global Opioid Use Disorder (OUD) Market by Region
7.1 North America Opioid Use Disorder (OUD) Market
7.1.1 North America Opioid Use Disorder (OUD) Market by Drug Class
7.1.1.1 North America Buprenorphine Market by Country
7.1.1.2 North America Methadone Market by Country
7.1.1.3 North America Naltrexone Market by Country
7.1.2 North America Opioid Use Disorder (OUD) Market by Route of Administration
7.1.2.1 North America Parenteral Market by Country
7.1.2.2 North America Oral Market by Country
7.1.3 North America Opioid Use Disorder (OUD) Market by Distribution Channel
7.1.3.1 North America Hospital Pharmacies Market by Country
7.1.3.2 North America Retail Pharmacies & Stores Market by Country
7.1.3.3 North America Online Pharmacies Market by Country
7.1.4 North America Opioid Use Disorder (OUD) Market by Country
7.1.4.1 US Opioid Use Disorder (OUD) Market
7.1.4.1.1 US Opioid Use Disorder (OUD) Market by Drug Class
7.1.4.1.2 US Opioid Use Disorder (OUD) Market by Route of Administration
7.1.4.1.3 US Opioid Use Disorder (OUD) Market by Distribution Channel
7.1.4.2 Canada Opioid Use Disorder (OUD) Market
7.1.4.2.1 Canada Opioid Use Disorder (OUD) Market by Drug Class
7.1.4.2.2 Canada Opioid Use Disorder (OUD) Market by Route of Administration
7.1.4.2.3 Canada Opioid Use Disorder (OUD) Market by Distribution Channel
7.1.4.3 Mexico Opioid Use Disorder (OUD) Market
7.1.4.3.1 Mexico Opioid Use Disorder (OUD) Market by Drug Class
7.1.4.3.2 Mexico Opioid Use Disorder (OUD) Market by Route of Administration
7.1.4.3.3 Mexico Opioid Use Disorder (OUD) Market by Distribution Channel
7.1.4.4 Rest of North America Opioid Use Disorder (OUD) Market
7.1.4.4.1 Rest of North America Opioid Use Disorder (OUD) Market by Drug Class
7.1.4.4.2 Rest of North America Opioid Use Disorder (OUD) Market by Route of Administration
7.1.4.4.3 Rest of North America Opioid Use Disorder (OUD) Market by Distribution Channel
7.2 Europe Opioid Use Disorder (OUD) Market
7.2.1 Europe Opioid Use Disorder (OUD) Market by Drug Class
7.2.1.1 Europe Buprenorphine Market by Country
7.2.1.2 Europe Methadone Market by Country
7.2.1.3 Europe Naltrexone Market by Country
7.2.2 Europe Opioid Use Disorder (OUD) Market by Route of Administration
7.2.2.1 Europe Parenteral Market by Country
7.2.2.2 Europe Oral Market by Country
7.2.3 Europe Opioid Use Disorder (OUD) Market by Distribution Channel
7.2.3.1 Europe Hospital Pharmacies Market by Country
7.2.3.2 Europe Retail Pharmacies & Stores Market by Country
7.2.3.3 Europe Online Pharmacies Market by Country
7.2.4 Europe Opioid Use Disorder (OUD) Market by Country
7.2.4.1 Germany Opioid Use Disorder (OUD) Market
7.2.4.1.1 Germany Opioid Use Disorder (OUD) Market by Drug Class
7.2.4.1.2 Germany Opioid Use Disorder (OUD) Market by Route of Administration
7.2.4.1.3 Germany Opioid Use Disorder (OUD) Market by Distribution Channel
7.2.4.2 UK Opioid Use Disorder (OUD) Market
7.2.4.2.1 UK Opioid Use Disorder (OUD) Market by Drug Class
7.2.4.2.2 UK Opioid Use Disorder (OUD) Market by Route of Administration
7.2.4.2.3 UK Opioid Use Disorder (OUD) Market by Distribution Channel
7.2.4.3 France Opioid Use Disorder (OUD) Market
7.2.4.3.1 France Opioid Use Disorder (OUD) Market by Drug Class
7.2.4.3.2 France Opioid Use Disorder (OUD) Market by Route of Administration
7.2.4.3.3 France Opioid Use Disorder (OUD) Market by Distribution Channel
7.2.4.4 Russia Opioid Use Disorder (OUD) Market
7.2.4.4.1 Russia Opioid Use Disorder (OUD) Market by Drug Class
7.2.4.4.2 Russia Opioid Use Disorder (OUD) Market by Route of Administration
7.2.4.4.3 Russia Opioid Use Disorder (OUD) Market by Distribution Channel
7.2.4.5 Spain Opioid Use Disorder (OUD) Market
7.2.4.5.1 Spain Opioid Use Disorder (OUD) Market by Drug Class
7.2.4.5.2 Spain Opioid Use Disorder (OUD) Market by Route of Administration
7.2.4.5.3 Spain Opioid Use Disorder (OUD) Market by Distribution Channel
7.2.4.6 Italy Opioid Use Disorder (OUD) Market
7.2.4.6.1 Italy Opioid Use Disorder (OUD) Market by Drug Class
7.2.4.6.2 Italy Opioid Use Disorder (OUD) Market by Route of Administration
7.2.4.6.3 Italy Opioid Use Disorder (OUD) Market by Distribution Channel
7.2.4.7 Rest of Europe Opioid Use Disorder (OUD) Market
7.2.4.7.1 Rest of Europe Opioid Use Disorder (OUD) Market by Drug Class
7.2.4.7.2 Rest of Europe Opioid Use Disorder (OUD) Market by Route of Administration
7.2.4.7.3 Rest of Europe Opioid Use Disorder (OUD) Market by Distribution Channel
7.3 Asia Pacific Opioid Use Disorder (OUD) Market
7.3.1 Asia Pacific Opioid Use Disorder (OUD) Market by Drug Class
7.3.1.1 Asia Pacific Buprenorphine Market by Country
7.3.1.2 Asia Pacific Methadone Market by Country
7.3.1.3 Asia Pacific Naltrexone Market by Country
7.3.2 Asia Pacific Opioid Use Disorder (OUD) Market by Route of Administration
7.3.2.1 Asia Pacific Parenteral Market by Country
7.3.2.2 Asia Pacific Oral Market by Country
7.3.3 Asia Pacific Opioid Use Disorder (OUD) Market by Distribution Channel
7.3.3.1 Asia Pacific Hospital Pharmacies Market by Country
7.3.3.2 Asia Pacific Retail Pharmacies & Stores Market by Country
7.3.3.3 Asia Pacific Online Pharmacies Market by Country
7.3.4 Asia Pacific Opioid Use Disorder (OUD) Market by Country
7.3.4.1 China Opioid Use Disorder (OUD) Market
7.3.4.1.1 China Opioid Use Disorder (OUD) Market by Drug Class
7.3.4.1.2 China Opioid Use Disorder (OUD) Market by Route of Administration
7.3.4.1.3 China Opioid Use Disorder (OUD) Market by Distribution Channel
7.3.4.2 Japan Opioid Use Disorder (OUD) Market
7.3.4.2.1 Japan Opioid Use Disorder (OUD) Market by Drug Class
7.3.4.2.2 Japan Opioid Use Disorder (OUD) Market by Route of Administration
7.3.4.2.3 Japan Opioid Use Disorder (OUD) Market by Distribution Channel
7.3.4.3 India Opioid Use Disorder (OUD) Market
7.3.4.3.1 India Opioid Use Disorder (OUD) Market by Drug Class
7.3.4.3.2 India Opioid Use Disorder (OUD) Market by Route of Administration
7.3.4.3.3 India Opioid Use Disorder (OUD) Market by Distribution Channel
7.3.4.4 South Korea Opioid Use Disorder (OUD) Market
7.3.4.4.1 South Korea Opioid Use Disorder (OUD) Market by Drug Class
7.3.4.4.2 South Korea Opioid Use Disorder (OUD) Market by Route of Administration
7.3.4.4.3 South Korea Opioid Use Disorder (OUD) Market by Distribution Channel
7.3.4.5 Singapore Opioid Use Disorder (OUD) Market
7.3.4.5.1 Singapore Opioid Use Disorder (OUD) Market by Drug Class
7.3.4.5.2 Singapore Opioid Use Disorder (OUD) Market by Route of Administration
7.3.4.5.3 Singapore Opioid Use Disorder (OUD) Market by Distribution Channel
7.3.4.6 Malaysia Opioid Use Disorder (OUD) Market
7.3.4.6.1 Malaysia Opioid Use Disorder (OUD) Market by Drug Class
7.3.4.6.2 Malaysia Opioid Use Disorder (OUD) Market by Route of Administration
7.3.4.6.3 Malaysia Opioid Use Disorder (OUD) Market by Distribution Channel
7.3.4.7 Rest of Asia Pacific Opioid Use Disorder (OUD) Market
7.3.4.7.1 Rest of Asia Pacific Opioid Use Disorder (OUD) Market by Drug Class
7.3.4.7.2 Rest of Asia Pacific Opioid Use Disorder (OUD) Market by Route of Administration
7.3.4.7.3 Rest of Asia Pacific Opioid Use Disorder (OUD) Market by Distribution Channel
7.4 LAMEA Opioid Use Disorder (OUD) Market
7.4.1 LAMEA Opioid Use Disorder (OUD) Market by Drug Class
7.4.1.1 LAMEA Buprenorphine Market by Country
7.4.1.2 LAMEA Methadone Market by Country
7.4.1.3 LAMEA Naltrexone Market by Country
7.4.2 LAMEA Opioid Use Disorder (OUD) Market by Route of Administration
7.4.2.1 LAMEA Parenteral Market by Country
7.4.2.2 LAMEA Oral Market by Country
7.4.3 LAMEA Opioid Use Disorder (OUD) Market by Distribution Channel
7.4.3.1 LAMEA Hospital Pharmacies Market by Country
7.4.3.2 LAMEA Retail Pharmacies & Stores Market by Country
7.4.3.3 LAMEA Online Pharmacies Market by Country
7.4.4 LAMEA Opioid Use Disorder (OUD) Market by Country
7.4.4.1 Brazil Opioid Use Disorder (OUD) Market
7.4.4.1.1 Brazil Opioid Use Disorder (OUD) Market by Drug Class
7.4.4.1.2 Brazil Opioid Use Disorder (OUD) Market by Route of Administration
7.4.4.1.3 Brazil Opioid Use Disorder (OUD) Market by Distribution Channel
7.4.4.2 Argentina Opioid Use Disorder (OUD) Market
7.4.4.2.1 Argentina Opioid Use Disorder (OUD) Market by Drug Class
7.4.4.2.2 Argentina Opioid Use Disorder (OUD) Market by Route of Administration
7.4.4.2.3 Argentina Opioid Use Disorder (OUD) Market by Distribution Channel
7.4.4.3 UAE Opioid Use Disorder (OUD) Market
7.4.4.3.1 UAE Opioid Use Disorder (OUD) Market by Drug Class
7.4.4.3.2 UAE Opioid Use Disorder (OUD) Market by Route of Administration
7.4.4.3.3 UAE Opioid Use Disorder (OUD) Market by Distribution Channel
7.4.4.4 Saudi Arabia Opioid Use Disorder (OUD) Market
7.4.4.4.1 Saudi Arabia Opioid Use Disorder (OUD) Market by Drug Class
7.4.4.4.2 Saudi Arabia Opioid Use Disorder (OUD) Market by Route of Administration
7.4.4.4.3 Saudi Arabia Opioid Use Disorder (OUD) Market by Distribution Channel
7.4.4.5 South Africa Opioid Use Disorder (OUD) Market
7.4.4.5.1 South Africa Opioid Use Disorder (OUD) Market by Drug Class
7.4.4.5.2 South Africa Opioid Use Disorder (OUD) Market by Route of Administration
7.4.4.5.3 South Africa Opioid Use Disorder (OUD) Market by Distribution Channel
7.4.4.6 Nigeria Opioid Use Disorder (OUD) Market
7.4.4.6.1 Nigeria Opioid Use Disorder (OUD) Market by Drug Class
7.4.4.6.2 Nigeria Opioid Use Disorder (OUD) Market by Route of Administration
7.4.4.6.3 Nigeria Opioid Use Disorder (OUD) Market by Distribution Channel
7.4.4.7 Rest of LAMEA Opioid Use Disorder (OUD) Market
7.4.4.7.1 Rest of LAMEA Opioid Use Disorder (OUD) Market by Drug Class
7.4.4.7.2 Rest of LAMEA Opioid Use Disorder (OUD) Market by Route of Administration
7.4.4.7.3 Rest of LAMEA Opioid Use Disorder (OUD) Market by Distribution Channel
Chapter 8. Company Profiles
8.1 Indivior PLC (Reckitt Benckiser Group plc)
8.1.1 Company Overview
8.1.2 Financial Analysis
8.1.3 Product and Regional Analysis
8.1.4 Research & Development Expenses
8.1.5 Recent strategies and developments:
8.1.5.1 Partnerships, Collaborations, and Agreements:
8.1.5.2 Acquisition and Mergers:
8.2 Collegium Pharmaceutical, Inc. (BioDelivery Sciences International, Inc.)
8.2.1 Company Overview
8.2.2 Financial Analysis
8.2.3 Research & Development Expenses
8.3 Orexo AB (Orexo US, Inc.)
8.3.1 Company Overview
8.3.2 Financial Analysis
8.3.3 Segmental and Regional Analysis
8.3.4 Research & Development Expenses
8.3.5 Recent strategies and developments:
8.3.5.1 Partnerships, Collaborations, and Agreements:
8.4 Alkermes PLC
8.4.1 Company Overview
8.4.2 Financial Analysis
8.4.3 Regional Analysis
8.4.4 Research & Development Expenses
8.4.5 Recent strategies and developments:
8.4.5.1 Trials and Approvals:
8.5 Titan Pharmaceuticals, Inc.
8.5.1 Company Overview
8.5.2 Financial Analysis
8.5.3 Segmental and Regional Analysis
8.5.4 Research & Development Expenses
8.5.5 Recent strategies and developments:
8.5.5.1 Trials and Approvals:
8.6 Camurus AB
8.6.1 Company Overview
8.6.2 Financial Analysis
8.6.3 Segmental and Regional Analysis
8.6.4 Research & Development Expenses
8.6.5 Recent strategies and developments:
8.6.5.1 Partnerships, Collaborations, and Agreements:
8.6.5.2 Trials and Approvals:
8.7 AstraZeneca PLC
8.7.1 Company Overview
8.7.2 Financial Analysis
8.7.3 Regional Analysis
8.7.4 Research & Development Expenses
8.7.5 Recent strategies and developments:
8.7.5.1 Acquisition and Mergers:
8.8 Hikma Pharmaceuticals PLC
8.8.1 Company Overview
8.8.2 Financial Analysis
8.8.3 Segmental and Regional Analysis
8.8.4 Research & Development Expenses
8.8.5 Recent strategies and developments:
8.8.5.1 Product Launches and Product Expansions:
8.9 Mallinckrodt PLC
8.9.1 Company Overview
8.9.2 Financial Analysis
8.9.3 Segmental and Regional Analysis
8.9.4 Research & Development Expense
8.10. Viatris, Inc.
8.10.1 Company Overview
8.10.2 Financial Analysis
8.10.3 Segmental Analysis
8.10.4 Research & Development Expense
Unique Offerings 
